STAT3 mediates cancer stem-like tumorsphere formation and PD-L1 expression to contribute radioresistance in HBV-positive hepatocellular carcinoma

IF 0.3 Q4 GASTROENTEROLOGY & HEPATOLOGY
Ai-Sheng Ho, Chun-Chia Cheng, Cheng-Liang Peng, Zong-Lin Sie, Chun Yeh, Shou-Dong Lee
{"title":"STAT3 mediates cancer stem-like tumorsphere formation and PD-L1 expression to contribute radioresistance in HBV-positive hepatocellular carcinoma","authors":"Ai-Sheng Ho,&nbsp;Chun-Chia Cheng,&nbsp;Cheng-Liang Peng,&nbsp;Zong-Lin Sie,&nbsp;Chun Yeh,&nbsp;Shou-Dong Lee","doi":"10.1002/aid2.13393","DOIUrl":null,"url":null,"abstract":"<p>We proposed that cancer stem cells (CSCs) survived and presented resistance to radiotherapy (RT) in hepatocellular carcinoma (HCC) cells. Interleukin 6 (IL-6) has been reported to be particularly involved in HCC tumorigenesis. Therefore, we intended to validate that IL-6 downstream STAT3-mediated CSCs formation and immune checkpoint PD-L1 expression in HCC, thus contributing to radioresistance. HBV-positive HCC tumorspheres were formed and exposed with X-ray irradiation, cell viability of which was measured consequently. Specific inhibitors targeting EGFR (by gefitinib), STAT3 (by BBI608), and HCC-targeted therapy sorafenib were investigated to suppress tumorsphere formation. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used for detecting STAT3-downstream PD-L1 and anti-apoptosis MCL1 and BCL2 gene expression in the PLC5-derived tumorspheres and STAT3-knockdown PLC5. We found that RT significantly inhibited HBV-positive Hep3B and PLC5 cell viability but not for HCC-derived stem-like tumorspheres cultured by EGF, IL-6, bFGF, and HGF. It revealed that tumorspheres presented radioresistance compared with the parental cells. Specifically, RT induces IFNs, EGF, and IL-6 expression, resulting in STAT3 phosphorylation. Kaplan–Meier plotter indicated that highly EGF (<i>p</i> = .0024), IL-6 (<i>p</i> = .12), and FGF2 (<i>p</i> = .0041) were associated with poor survival probability in patients with HBV-positive HCC. We further demonstrated that BBI608 and sorafenib significantly suppressed PLC5 cell viability and PLC5-derived tumorsphere formation. To investigate the mechanism of CSC-presented radioresistance, STAT3 and STAT3-downstream genes, including PD-L1 and anti-apoptosis MCL1 and BCL2, were detected using qPCR. We demonstrated higher STAT3, PD-L1, MCL1, and BCL2 in Hep3B- and PLC5-derived CSCs compared to PLC5. In addition, knockdown of STAT3 reduced cell proliferation in PLC5 cells, resulting in down-regulation of IL-6-mediated PD-L1 and BCL-2. Meanwhile, we found that knockdown of STAT3 significantly improved RT-mediated suppression of tumorsphere formation. In conclusion, we found that CSCs presented radioresistance and figured out which may be mediated by STAT3 in HBV-positive HCC.</p>","PeriodicalId":7278,"journal":{"name":"Advances in Digestive Medicine","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aid2.13393","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Digestive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/aid2.13393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We proposed that cancer stem cells (CSCs) survived and presented resistance to radiotherapy (RT) in hepatocellular carcinoma (HCC) cells. Interleukin 6 (IL-6) has been reported to be particularly involved in HCC tumorigenesis. Therefore, we intended to validate that IL-6 downstream STAT3-mediated CSCs formation and immune checkpoint PD-L1 expression in HCC, thus contributing to radioresistance. HBV-positive HCC tumorspheres were formed and exposed with X-ray irradiation, cell viability of which was measured consequently. Specific inhibitors targeting EGFR (by gefitinib), STAT3 (by BBI608), and HCC-targeted therapy sorafenib were investigated to suppress tumorsphere formation. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used for detecting STAT3-downstream PD-L1 and anti-apoptosis MCL1 and BCL2 gene expression in the PLC5-derived tumorspheres and STAT3-knockdown PLC5. We found that RT significantly inhibited HBV-positive Hep3B and PLC5 cell viability but not for HCC-derived stem-like tumorspheres cultured by EGF, IL-6, bFGF, and HGF. It revealed that tumorspheres presented radioresistance compared with the parental cells. Specifically, RT induces IFNs, EGF, and IL-6 expression, resulting in STAT3 phosphorylation. Kaplan–Meier plotter indicated that highly EGF (p = .0024), IL-6 (p = .12), and FGF2 (p = .0041) were associated with poor survival probability in patients with HBV-positive HCC. We further demonstrated that BBI608 and sorafenib significantly suppressed PLC5 cell viability and PLC5-derived tumorsphere formation. To investigate the mechanism of CSC-presented radioresistance, STAT3 and STAT3-downstream genes, including PD-L1 and anti-apoptosis MCL1 and BCL2, were detected using qPCR. We demonstrated higher STAT3, PD-L1, MCL1, and BCL2 in Hep3B- and PLC5-derived CSCs compared to PLC5. In addition, knockdown of STAT3 reduced cell proliferation in PLC5 cells, resulting in down-regulation of IL-6-mediated PD-L1 and BCL-2. Meanwhile, we found that knockdown of STAT3 significantly improved RT-mediated suppression of tumorsphere formation. In conclusion, we found that CSCs presented radioresistance and figured out which may be mediated by STAT3 in HBV-positive HCC.

Abstract Image

STAT3 介导癌症干样瘤球的形成和 PD-L1 的表达,导致 HBV 阳性肝细胞癌的放射抗性
我们提出,癌症干细胞(CSCs)在肝细胞癌(HCC)细胞中存活并对放疗(RT)产生抗性。据报道,白细胞介素6(IL-6)尤其参与了HCC的肿瘤发生。因此,我们打算验证 IL-6 下游 STAT3 介导的 CSCs 形成和免疫检查点 PD-L1 在 HCC 中的表达,从而导致放射抗性。HBV 阳性 HCC 瘤球形成后接受 X 射线照射,随后测定其细胞活力。研究人员研究了针对表皮生长因子受体(吉非替尼)、STAT3(BBI608)的特异性抑制剂,以及抑制肿瘤球形成的 HCC 靶向疗法索拉非尼。逆转录-定量聚合酶链反应(RT-qPCR)用于检测 STAT3 下游 PD-L1 和抗凋亡 MCL1 和 BCL2 基因在 PLC5 衍生的瘤球和 STAT3 敲除的 PLC5 中的表达。我们发现 RT 能明显抑制 HBV 阳性 Hep3B 和 PLC5 细胞的存活率,但不能抑制 EGF、IL-6、bFGF 和 HGF 培养的 HCC 源性干样瘤球的存活率。研究发现,与亲代细胞相比,肿瘤球具有放射抗性。具体来说,RT会诱导IFNs、EGF和IL-6的表达,导致STAT3磷酸化。Kaplan-Meier plotter表明,EGF(p = .0024)、IL-6(p = .12)和FGF2(p = .0041)的高表达与HBV阳性HCC患者的低生存率相关。我们进一步证实,BBI608 和索拉非尼能显著抑制 PLC5 细胞活力和 PLC5 衍生肿瘤球的形成。为了研究CSC表现出放射抗性的机制,我们使用qPCR检测了STAT3和STAT3下游基因,包括PD-L1和抗凋亡的MCL1和BCL2。与 PLC5 相比,我们发现 Hep3B 和 PLC5 衍生的 CSC 中 STAT3、PD-L1、MCL1 和 BCL2 的含量更高。此外,敲除 STAT3 会减少 PLC5 细胞的增殖,导致 IL-6 介导的 PD-L1 和 BCL-2 下调。同时,我们发现敲除 STAT3 能显著改善 RT 介导的瘤球形成抑制作用。总之,我们发现 CSCs 具有放射抗性,并推测出这可能是由 STAT3 在 HBV 阳性 HCC 中介导的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Digestive Medicine
Advances in Digestive Medicine GASTROENTEROLOGY & HEPATOLOGY-
自引率
33.30%
发文量
42
期刊介绍: Advances in Digestive Medicine is the official peer-reviewed journal of GEST, DEST and TASL. Missions of AIDM are to enhance the quality of patient care, to promote researches in gastroenterology, endoscopy and hepatology related fields, and to develop platforms for digestive science. Specific areas of interest are included, but not limited to: • Acid-related disease • Small intestinal disease • Digestive cancer • Diagnostic & therapeutic endoscopy • Enteral nutrition • Innovation in endoscopic technology • Functional GI • Hepatitis • GI images • Liver cirrhosis • Gut hormone • NASH • Helicobacter pylori • Cancer screening • IBD • Laparoscopic surgery • Infectious disease of digestive tract • Genetics and metabolic disorder • Microbiota • Regenerative medicine • Pancreaticobiliary disease • Guideline & consensus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信